KRRO

Korro Bio, Inc. (KRRO) - Q1 2026 Filing Summary

Business Context and Reporting Period

This summary covers the Quarterly Report on Form 10-Q for Korro Bio, Inc. for the period ended March 31, 2026. Korro Bio is a biopharmaceutical company developing genetic medicines using its proprietary oligonucleotide promoted editing of RNA (OPERA) platform. The company is currently pre-commercial, with no approved products, and relies on equity financing and collaboration revenue to fund operations. As of May 4, 2026, there were 14,422,571 shares of common stock outstanding.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Collaboration revenue dropped to $0 from $2.55 million in Q1 2025. This is due to a 12-month pause in the research collaboration with Novo Nordisk effective November 2025, during which no revenue is recognized.
• Expense Reduction: Total operating expenses decreased by $7.13 million (26%) year-over-year.
  • R&D Expenses: Decreased by $6.79 million, primarily driven by a $5.4 million reduction in external expenses for the KRRO-110 (AATD) program following the termination of its Phase 1/2a REWRITE clinical trial in Q1 2026. This was partially offset by a $3.3 million increase in KRRO-121 (UCD) external expenses.
  • Personnel Costs: Decreased by $2.5 million due to workforce reductions implemented in May and November 2025.
• Capital Raise: In March 2026, the company completed a private placement (PIPE) raising approximately $85.0 million in gross proceeds. Additionally, $5.1 million was raised via an At-The-Market (ATM) offering in January 2026.
• Liquidity Improvement: Total cash, cash equivalents, and marketable securities increased significantly from $86.2 million at year-end 2025 to $157.1 million as of March 31, 2026, extending the cash runway into the second half of 2028.

Guidance, Outlook, and Risks

• Development Pipeline:
  • KRRO-121: The lead development candidate for hyperammonemia (UCD and HE). The company anticipates submitting a regulatory filing to enable a first-in-human trial in the second half of 2026.
  • AATD Program: Following the termination of the KRRO-110 trial, the company is advancing a next-generation GalNAc-conjugated candidate. A development candidate nomination is expected in Q2 2026.
• Collaboration Status: The Novo Nordisk collaboration remains paused for 12 months. The company expects to recognize revenue from this agreement through 2028 as the hold period concludes.
• Restructuring: The company implemented a workforce reduction of approximately 34% in November 2025 to extend its cash runway. Remaining severance payments are expected to be completed by Q3 2026.
• Key Risks:
  • Clinical Failure: The company has no approved products and faces high risks associated with the novel RNA editing technology. The failure of the KRRO-110 trial highlights the uncertainty of clinical outcomes.
  • Capital Needs: Despite the recent raise, the company expects to incur significant losses for the foreseeable future and will require substantial additional funding to advance clinical trials and commercialization.
  • Regulatory Uncertainty: There are no definitive regulatory guidelines for RNA editing therapies, which may complicate the approval process.

Investor Verification Checklist

• Verify the specific timeline and milestones for the KRRO-121 regulatory filing expected in H2 2026.
• Confirm the terms and potential restart date of the paused Novo Nordisk collaboration.
• Review the detailed breakdown of the $85 million PIPE financing, including the exercise price of pre-funded warrants and any dilution impact.
• Assess the remaining cash runway based on current burn rates and the impact of the November 2025 workforce reduction.
• Monitor the progress of the new GalNAc-conjugated AATD candidate nomination expected in Q2 2026.